Healthcare Industry News: hypothermia
News Release - April 23, 2014
Jeffrey Gold Joins myoscience as President and Chief Operating OfficerREDWOOD CITY, Calif., April 23, 2014 -- (Healthcare Sales & Marketing Network) -- myoscience, inc. is pleased to announce the addition of Jeffrey Gold to the team as President and Chief Operating Officer (COO). Mr. Gold is an accomplished executive, having held posts as Chief Executive for Velomedix and CryoVascular Systems as well as Chief Operating Officer for CardioThoracic Systems.
"Jeff's leadership and extensive experience driving operational excellence makes him an exceptional addition to myoscience as we expand our global commercial presence in both aesthetic and therapeutic channels," said Clint Carnell, CEO of myoscience.
Mr. Gold was most recently the President & CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest. Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices.
"I am thrilled to be joining myoscience at such an exciting point in their growth," said Gold. "My previous experience and the current needs of the company align perfectly and I look forward to guiding the business towards further success."
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera:o system. The iovera:o system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
(C) 2014 myoscience. All rights reserved. iovera* and Focused Cold Therapy are trademarks of myoscience.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.